Compliance Team
Angels Den

Dear User,

You may have heard about the new General Data Protection Regulation (“GDPR”), that comes into effect May 25, 2018.

We would like to ensure you that your personal data is safe with us. Please read the details regarding the processing of your personal data and if you agree with the processing as described below, please click the ‘I agree’ button.

Please be informed that you can withdraw this consent at any time.

1) What data are we talking about?

We are disclosing details regarding the processing of personal data that is collected within our calls and in connection with your use of Angels Den’s platform, Websites and other functionalities of Angels Den, including those saved in cookies files.

2) Who will be the controller of your data?

Angels Den Funding Limited (hereinafter referred to as AD) will be the controller of your data (Angels Den means all entities from the Angels Den capital group, which includes Angels Den Funding Limited with its registered office in London and all entities related to it and dependent on it) and only our Trusted Partners.

3) Why do we want to process your data?

We process this data for the purposes described in our Privacy Policy, including:
- compliance with any legal requirements and obligations,
- ensuring that content from our Website is presented in the most effective manner for you,
- marketing purposes,
- providing you with our services (including the completion and support of immediate activity required to provide you with information and deliver products and/or services that you request and to deliver any contracts entered into with you), or
- as otherwise explained in this privacy policy or by any communication by us.
Where you have explicitly consented to be contacted for such purposes, we use your personal data to provide information on our new and existing products and services.

4) To whom can we transfer data?

In accordance with applicable law, we may transfer your data to entities processing it at our request, e.g. marketing agencies, subcontractors of our services and entities authorized to obtain data under applicable law, e.g. courts or law enforcement agencies - of course only if they submit a request based on an applicable legal basis. Furthermore, we will transfer your data to Trusted Partners outside the European Union – to the USA – under the EU-U.S. Privacy Shield Framework.

5) What are your rights to your data?

You have the right to request access to, correct, delete your personal data. You can also withdraw consent to processing of personal data, raise objections and use other rights granted under GDPR (i.e. right to data portability).

6) Use of cookies

We use cookies to give you the best experience on our Website. This means that we have placed cookies on your device. If you continue without changing your cookie settings, we assume that you consent to our use of cookies on this device. You can change your cookie settings at any time but if you do, you may lose some functionality on our Website. More information can be found in our Privacy Policy.

In connection with the above, I agree to the processing of my personal data by Angels Den and its Trusted Partners. I confirm that I understand that my personal data is being collected as part of my phone calls, use of AD’s online platform, Websites, and other functionalities of AD, including the data saved in cookie files. I also consent to profiling in order to allow Angels Den and its Trusted Partners the provision of better services (including for analytical purposes). Your data will only be processed on a valid lawful basis in accordance with applicable data protection laws. The processing of your personal data for marketing purposes (including statistical analysis) by AD is based on the firm's legitimate interest. The processing for marketing purposes by our Trusted Partners is only possible if we receive your freely given consent. We will also process your personal data to fulfil our contractual obligations to you as contained in AD’s Terms and Conditions of the use of our Website and services. Therefore, this data will be processed on another lawful basis – ‘contract’. We will also process your data to comply with our legal obligations for our Service (such as anti money laundering and know your customer requirements), which is also a valid lawful basis in accordance with applicable data protection laws.

Expressing this consent is voluntary and you can withdraw at any time.

If you have any doubts or questions about the use of your personal data, please do not hesitate to contact me via email. I’m happy to assist.

Compliance Team
Angels Den
cl@angelsden.com

I Agree
Not Now

FLOMARK LTD

Medtech company developing patented devices and data analytics to monitor fluid balance.

£ 0
27 Days left

0% of minimum goal raised

Lead investor: Sam Kremer

Minimum Target

£ 20,000

Minimum investment amount

£ 10,000

Maximum Target

£ 200,000

Maximum investment amount

£ 200,000
Sign In to see more

Investment Opportunity

Flomark Ltd is a business which designs and develops medical devices to sell under licence. These devices are much cheaper and more accurate than the competition and create a system which produces fluid balance data. We then sell analytics using this data to help inform clinical care.

THE IDEA
Products & Services

We have an innovative flow meter which is very accurate at low flow rates, reliable, and cheap enough to be used in consumable devices. This allows direct measurement of flow rates using our devices which are much cheaper than the competition. Using a suite of such devices (consumable and electronic devices for infusion, and the same pairing for urine output) is the only way to achieve end-to-end automated fluid balance measurement. Providing reliable fluid balance data will decrease Acute Kidney Injury by 33% and Fluid Overload by 56%, giving huge reductions in morbidity and mortality, as well as their associated costs.

Problem Solved

Fluid balance (fluid input v output) is fundamental to patient care. Data is inaccurate and not relied upon in clinical decision making. This leads to Acute Kidney Injury and Fluid Overload, contributing to more than 2m deaths per year globally, costs the UK £1Bn pa and the US £20Bn pa.

For nil-by-mouth patients, fluid input is via infusions. Gravity IV sets (‘drips’) are 85% inaccurate, and infusion pumps are overpriced and have poor accuracy. For catheterised patients, urine output is monitored manually and is 39% inaccurate, even in ICU.

Fluid balance is the last parameter which is not automated. Patient care suffers, and the market is poorly served by 1970s technology.

Revenue Model

We have four physical devices (two consumable, two electronic). The high volume, low margin consumable devices will be sold via licensing agreements. The infusion consumable matches the market average price (roughly 50-60p, COG 30p), with 3-4p to Flomark Ltd. The urine output consumable will match the price of a urine collection bag (£2.50), with 10p to Flomark Ltd. The infusion electronic device will sell for £800 (infusion pumps cost around £1600), COG £200. The urine output electronic device will sell for £200, COG £50.

The data product will be sold as a subscription for £250k per trust per year. This is around 10% of the £2.5m savings per hospital that the data would generate.

Exit Strategy
You have to log in or register to see this information.

The Idea

Products & Services

We have an innovative flow meter which is very accurate at low flow rates, reliable, and cheap enough to be used in consumable devices. This allows direct measurement of flow rates using our devices which are much cheaper than the competition. Using a suite of such devices (consumable and electronic devices for infusion, and the same pairing for urine output) is the only way to achieve end-to-end automated fluid balance measurement. Providing reliable fluid balance data will decrease Acute Kidney Injury by 33% and Fluid Overload by 56%, giving huge reductions in morbidity and mortality, as well as their associated costs.

Problem Solved

Fluid balance (fluid input v output) is fundamental to patient care. Data is inaccurate and not relied upon in clinical decision making. This leads to Acute Kidney Injury and Fluid Overload, contributing to more than 2m deaths per year globally, costs the UK £1Bn pa and the US £20Bn pa.

For nil-by-mouth patients, fluid input is via infusions. Gravity IV sets (‘drips’) are 85% inaccurate, and infusion pumps are overpriced and have poor accuracy. For catheterised patients, urine output is monitored manually and is 39% inaccurate, even in ICU.

Fluid balance is the last parameter which is not automated. Patient care suffers, and the market is poorly served by 1970s technology.

Revenue Model

We have four physical devices (two consumable, two electronic). The high volume, low margin consumable devices will be sold via licensing agreements. The infusion consumable matches the market average price (roughly 50-60p, COG 30p), with 3-4p to Flomark Ltd. The urine output consumable will match the price of a urine collection bag (£2.50), with 10p to Flomark Ltd. The infusion electronic device will sell for £800 (infusion pumps cost around £1600), COG £200. The urine output electronic device will sell for £200, COG £50.

The data product will be sold as a subscription for £250k per trust per year. This is around 10% of the £2.5m savings per hospital that the data would generate.

Exit Strategy
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.

Website

www.flomark.co.uk/

Location

CHESHAM

Gallery